Peptic ulcer disease (PUD) remains a prevalent gastrointestinal disorder with significant morbidity and mortality rates. The management of PUD has evolved significantly over the past few decades due to advancements in diagnostic tools, pharmacological treatments, and an improved understanding of the disease's pathophysiology.
Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary etiological factors for PUD. The disruption of the mucosal barrier, leading to gastric acid damage, is a common pathway in ulcer development. Understanding this pathophysiology has been pivotal in designing effective treatment strategies.
Endoscopy remains the gold standard for diagnosing PUD, providing direct visualization and biopsy opportunities. However, non-invasive tests for H. pylori, such as urea breath tests and stool antigen tests, have improved diagnostic accuracy and patient comfort.
Proton pump inhibitors (PPIs) and H. pylori eradication therapy form the cornerstone of PUD management. PPIs suppress gastric acid secretion, promoting ulcer healing, while H. pylori eradication prevents ulcer recurrence. Recent studies highlight the potential of potassium-competitive acid blockers as a promising alternative to PPIs.
For NSAID-induced ulcers, discontinuing NSAIDs is ideal. However, if this is not feasible, co-prescription of PPIs or the use of selective cyclooxygenase-2 inhibitors can mitigate gastrointestinal risks.
While the need for surgical intervention has decreased due to effective medical therapy, it remains crucial for managing complications such as bleeding, perforation, or gastric outlet obstruction.
The management of PUD has come a long way, with advancements in understanding its pathophysiology, diagnostic methods, and treatment options. Continual research and innovation are imperative to further enhance patient outcomes and reduce disease burden.
1.
Global warming could be driving up women's cancer risk, find researchers
2.
Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.
3.
Survey shows cancer anxiety has impact well beyond the individual diagnosed
4.
MRI can save rectal cancer patients from surgery, study suggests
5.
Glioma Outcomes Shaped by Subtype More Than Tx Sequence
1.
Rehabilitation After Organ-Conserving Cancer Surgery
2.
Practical Breakthroughs in Oncology Across Clinical Settings
3.
Gynecologic Oncology: Advances, Education, and Clinical Excellence
4.
Breaking Down the Different Types of Lymphoma: What You Need to Know
5.
RNA-Targeting Chimeras in Cancer: Mechanisms, Clinical Advances, and Future Directions
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Cancer Care: From Awareness to Recovery
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation